Emmaus Life Sciences, Inc.
EMMA · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $1 | $5 | $13 | $82 |
| - Cash | $1 | $3 | $2 | $2 |
| + Debt | $33 | $33 | $31 | $30 |
| Enterprise Value | $32 | $35 | $42 | $110 |
| Revenue | $17 | $30 | $18 | $21 |
| % Growth | -43.7% | 60.9% | -10.8% | – |
| Gross Profit | $15 | $28 | $16 | $17 |
| % Margin | 92.8% | 95.5% | 85.9% | 83.9% |
| EBITDA | -$1 | $4 | -$5 | -$13 |
| % Margin | -5.5% | 12.2% | -29.9% | -61.9% |
| Net Income | -$6 | -$4 | -$11 | -$16 |
| % Margin | -38.7% | -12.6% | -57.8% | -77.4% |
| EPS Diluted | -0.1 | -0.07 | -0.21 | -0.32 |
| % Growth | -42.2% | 66.5% | 34.4% | – |
| Operating Cash Flow | -$2 | -$2 | -$5 | -$1 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$2 | -$2 | -$5 | -$1 |